1603 GMT - The results of a U.S. probe into the pharmaceutical sector are imminent, but any potential hits from President Trump's tariffs and drug-price policies seem to be already priced in by Swiss pharma stocks, Vontobel's Stefan Schneider says in a note. Vontobel estimates U.S. drug prices could be cut by between 5% and 33%, but finds that this is already factored into Swiss pharma stock prices. According to Vontobel's analysis, Roche shares could see a movement from 0% in its base-case scenario to a 7% drop in its worst-case scenario, while Novartis shares could either rise or fall by 8%. This means the outcome of the U.S. investigation could also trigger share-price rises as a clearer picture emerges, the analyst says. Shares in Novartis and Roche close 0.9% and 0.4% lower, respectively. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
August 22, 2025 12:03 ET (16:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。